**Name of journal: World Journal of Stem Cells**

**ESPS Manuscript NO: 12842**

**Columns: REVIEW**

**Methods of induced pluripotent stem cells for clinical application**

Seki T *et al*. Methods of induced pluripotent stem cells

Tomohisa Seki, Keiichi Fukuda

**Tomohisa Seki,** Department of Emergency and Critical Care Medicine, Keio University School of Medicine, Tokyo 160-8582, Japan

**Tomohisa Seki, Keiichi Fukuda,** Department of Cardiology, Keio University School of Medicine, Tokyo 160-8582, Japan

**Author contributions:** Seki T prepared most of the paper; Fukuda K provided advice and proofread the paper.

**Supported by** The Support Program to break the bottlenecks at R&D Systems for accelerating the practical use of Health Research Outcome, the Highway Program for the Realization of Regenerative Medicine, and Health Labour Sciences Research Grant.

**Correspondence to: Keiichi Fukuda, MD, PhD**, **FACC, Professor and Chair,** Department of Cardiology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku. Tokyo 160-8582, Japan. kfukuda@a2.keio.jp

**Telephone:** +81-3-53633874  **Fax:** +81-3-53633875

**Received:** July 27, 2014 **Revised:** September 18, 2014

**Accepted:** October 23, 2014

**Published online:**

**Abstract**

Reprograming somatic cells using exogenetic gene expression represents a groundbreaking step in regenerative medicine. Induced pluripotent stem cells (iPSCs) are expected to yield novel therapies with the potential to solve many issues involving incurable diseases. In particular, applying iPSCs clinically holds the promise of addressing the problems of immune rejection and ethics that have hampered the clinical applications of embryonic stem cells. However, as iPSC research has progressed, new problems have emerged that need to be solved before the routine clinical application of iPSCs can become established. In this review, we discuss the current technologies and future problems of human iPSC generation methods for clinical use.

© 2014 Baishideng Publishing Group Inc. All rights reserved.

**Key words:** Induced pluripotent stem cells; Cell reprogramming

**Core tip:** Each iPSC methodology has advantages and disadvantages, as in the case of autologous versus allogenic transplantation, and the choice of appropriate strategy may vary depending on the intended use. Additionally, to avoid tumorigenesis and to establish effective differentiation into the intended cells, further investigation is needed to identify the most suitable iPSC line and how these lines should be selected.

Seki T, Fukuda K. Methods of induced pluripotent stem cells for clinical application. *World J Stem Cells* 2014, In press

**INTRODUCTION**

In 2006, Yamanaka *et al*[[1](#_ENREF_1)] established a novel method of reprogramming mouse somatic cells using exogenetic expression of genes related to pluripotency. The cell lines established by this group were named induced pluripotent stem cells (iPSCs) and demonstrated the same pluripotency and self-renewal properties that are characteristic of embryonic stem cells (ESCs). The following year, the same group also succeeded in generating iPSCs from human somatic cells[[2](#_ENREF_2)]. These groundbreaking steps have been expected to lead to novel regenerative cell therapies with the potential to solve many problems surrounding incurable diseases. In particular, the clinical application of iPSCs is expected to solve the problems of immune rejection and ethics that are currently key obstacles in the clinical use of ESCs. However, as research into iPSCs has progressed, new problems to solve have emerged before iPSCs can be established as cell sources for patients. In this review, we discuss the current technology and future problems surrounding human iPSC generation methods for clinical applications.

**BENEFITS AND PROBLEMS OF ESCS AND IPSCS IN CLINICAL APPLICATION**

For treating diseases that lack self-repairing cells, the transplantation of artificially generated cells is one attractive means for curing the diseases. In fact, regenerative cell transplantation therapies have been expected to treat incurable diseases, such as spinal cord injury[[3](#_ENREF_3)], neurodegenerative disease[[4](#_ENREF_4)], heart failure[[5](#_ENREF_5),[6](#_ENREF_6)], diabetes[[7](#_ENREF_7)], and retinal disease[[8](#_ENREF_8)].

ESCs have the capacity to self-renew and differentiate into cells of the three germ layers. The development of suitable cultivation systems for maintaining the pluripotency of ESCs marked their promise as a cell source for regenerative medicine since human ESCs were first generated in 1998[[9](#_ENREF_9)]. Numerous efforts have been made since then to realize the promise of making specific differentiated cells from ESCs. However, the ethical problem of needing human zygotes to generate human ESCs has remained unsolved. Additionally, immune rejection remains an issue because of the limited number of ESC cell lines and the ability of the cell lines to match the huge number of HLA type combinations found in patients.

These problems with ESCs and the ongoing need for regenerative therapies drove further research efforts, such as Dr. Yamanaka’s 2006 success in generating iPSCs from somatic mouse cells[[1](#_ENREF_1)] and reports in 2007 by Yamanaka *et al*[2] and Thomson *et al*[[10](#_ENREF_10)] of the successful generation of human iPSCs. In the original mouse work, 24 transcription factors showing high expression in ESCs were chosen as candidate reprogramming triggers [[1](#_ENREF_1)]. Finally, the forced expression of *OCT3/4*, *SOX2*, *KLF4*, and *C-MYC* together with a retrovirus evoked mouse somatic cell reprogramming into the pluripotent state, and the same combination of four factors forced human fibroblasts into iPSCs[[2](#_ENREF_2)]. At the same time, Thomson *et al*[[10](#_ENREF_10)] successfully reprogrammed human fibroblasts using the combination of *OCT4*, *SOX2*, *NANOG*, and *LIN28*. These methods attracted much attention because these iPSC lines could potentially overcome the immune rejection and ethical issues hampering the development of ESCs for clinical use. Therefore, iPSCs showed promise as the breakthrough technology in regenerative medicine.

**COMBINATION OF REPROGRAMMING FACTORS FOR IPSC GENERATION**

Since iPSC generation methods were first reported, numerous efforts have been made to adapt them to clinical applications[5,[11](#_ENREF_11)]. The reported generation methods vary in the combinations of reprogramming factors, vehicles for exogenous genes, and cell types to generate the iPSCs. Therefore, current discussions in the literature focus on selecting the most appropriate iPSC generation method for clinical use.

In relation to the combination of reprogramming factors for iPSC generation, the first reported combination of *OCT3/4*, *SOX2*, *KLF4*, and *C-MYC*, known as the Yamanaka factors, are generally used for iPSC generation. Combining only three of these factors and omitting *C-MYC* was also reported to achieve successful iPSC generation, although with reduced reprogramming efficiency[[12](#_ENREF_12),[13](#_ENREF_13)]. These alternative methods arose following concerns about using *C-MYC*, which is a known oncogene in human cells. Another group also reported the generation of mouse iPSCs, which showed more efficient germline transmission in chimeric formation experiments using the combination of *OCT3/4*, *SOX2*, *KLF4*, and *TBX3* as reprogramming factors[[14](#_ENREF_14)]. Subsequently, iPSC generation using *L-MYC* instead of *C-MYC* was reported with improved efficiency in both reprogramming somatic cells and germline transmission of generated iPSCs[[15](#_ENREF_15)]. Furthermore, *GLIS1* was also reported as a candidate alternate factor for *C-MYC* that showed high reprogramming efficiency, less incomplete reprogramming, and reduced tumor formation in iPSC-derived mice[[16](#_ENREF_16)]. Recently, improved iPSC quality was also achieved by introducing *Zscan4,* which is highly expressed at the zygotic genome activation stage. Forced expression of *Zscan4* in combination with the Yamanaka factors improved iPSC quality as demonstrated by tetraploid complementation[[17](#_ENREF_17)].

Recently, lineage-specific genes were substituted for *OCT3/4* or SOX2[[18](#_ENREF_18)]. In this report, *OCT3/4* was replaced with an early mesendodermal lineage marker, such as *GATA3*, and *SOX2* was replaced with an early ectodermal lineage marker, such as *ZNF521,* in reprogramming using the Yamanaka factors. This finding raised the possibility that *OCT3/4* and *SOX2* might act as lineage specifiers for cell reprogramming and showed that reprogramming factors are not limited to genes associated with pluripotency[[18](#_ENREF_18)].

Although methods for checking the quality of iPSCs such as germline transmission experiments are not applicable to human iPSCs, such studies can be useful for seeking the best combination of reprogramming factors to generate human iPSCs that are of sufficient quality for clinical use.

**GENE-DELIVERY VEHICLES FOR IPSC GENERATION**

Gene-delivery vehicles are also an important for selecting a suitable method of iPSC generation for clinical use, and to date, many gene delivery vehicles have proven to be applicable to iPSC generation. Initially, retrovirus vectors, such as pMXs[[2](#_ENREF_2),[19](#_ENREF_19),[20](#_ENREF_20)], pLib[[21](#_ENREF_21)] or pMSCV[[22](#_ENREF_22),[23](#_ENREF_23)], were used for the delivery of reprogramming factors into somatic cells. Importantly, transgenes introduced with retrovirus vectors have been known to be silenced in pluripotent states[[22](#_ENREF_22),[24](#_ENREF_24)], and therefore, silencing of transgene expression in iPSCs has been thought to be an important result of successful reprogramming[[25](#_ENREF_25)]. Lentiviral vectors have also been used for successful iPSC generation because lentiviral vectors achieve a higher efficiency of infection than retrovirus vectors[[10](#_ENREF_10),[26](#_ENREF_26)]. Importantly, transgenes introduced by lentiviral vectors are more resistant to being silenced in pluripotent states than those transtenes introduced by retrovirus vectors[[27](#_ENREF_27)].

The genomic integration of transgenes that occurs as a result of these virus vectors was thought to be a problem for the clinical use of iPSCs because the delivered transgenes have the potential to be reactivated after cell reprogramming and thus drive oncogenesis in the iPSC-derived cells[[28](#_ENREF_28)]. Furthermore, these transgenes have the potential to disrupt functional genes, even if they are silenced and not expressed. Therefore, many efforts have been made to generate iPSCs without the genomic insertions. For example adenovirus vectors are routinely used to introduce transient gene expression in target cells. Furthermore, a replication-defective pHIHG-Ad2 vector, was used to successfully reprogram somatic cells into iPSCs[[29](#_ENREF_29)]. Therefore, although adenoviral vectors still integrate into the genome of target cells at extremely low frequencies[[30](#_ENREF_30)] and the reprogramming efficiency is significantly lower than that with retrovirus, this method generates iPSCs that do not transfer residual transgenes into the host genomes.

More recently, a Cre-deletable lentivirus system was used for the successful generation of iPSCs[[31](#_ENREF_31)]. However, although these systems can avoid transgene reactivation, the risk of gene breaks being introduced near the insertion site is present because the LoxP sequence remains in the host genome after removing the insert sequence by Cre recombinase[[32](#_ENREF_32)].

In addition to virus vectors, the Sendai virus was also successfully used to generate iPSCs[[33](#_ENREF_33),[34](#_ENREF_34)]. The Sendai virus genome is negative-sense single-stranded RNA. Because replication occurs in the cytoplasm, this virus vector does not pose a danger of genome insertion. Therefore, this method solves both problems of gene disruption near the insertion site and reactivation of transgenes. Additionally, the residual Sendai virus RNA can be removed from the infected cells using siRNA[[35](#_ENREF_35)], and temperature-sensitive mutations[[36](#_ENREF_36)] were also reported, improving the potential clinical suitability of this iPSC generation method.

As another approach for safe iPSC generation, a virus-free reprogramming method has received attention. For example, an iPSC generation method using episomal vectors has also been developed[[37-40](#_ENREF_37)]. The early attempts using this method yielded lower efficiencies of successful reprogramming than those achieved using retrovirus, and only a low percentage of iPSC lines generated using this method had no plasmid integration. However, later modifications of the episomal vector method yielded a higher reprogramming efficiency using a combination of plasmids encoding *OCT3/4*, *SOX2*, *KLF4*, *L-MYC*, *LIN28*, and shRNA for *TP53*[[41](#_ENREF_41),[42](#_ENREF_42)].

Generating iPSCs using a piggyBac transposon was reported as another method to avoid the reactivation of residual transgenes and gene breaks in the host genome[[43-45](#_ENREF_43)]. The piggyBac transposon is a moth-derived DNA transposon[[46](#_ENREF_46)] that is highly active in mammalian cells and able to be completely eliminated from the host genome using the piggyBac transposase[[47](#_ENREF_47)]. Despite generating integration-free iPSCs by this method, the reported reprogramming efficiency was lower than that with retrovirus, and thus further improvements are needed[[43-45](#_ENREF_43)].

As another way to avoid introducing genetic material, introducing reprogramming factors such as RNAs or proteins has attracted much attention. Indeed, the direct delivery of synthetic mRNAs has been shown to successfully reprogram somatic cells to a pluripotent state[[48](#_ENREF_48)]. In this study, in vitro transcribed RNAs were modified to avoid the endogenous antiviral cell defense. As a result, this method achieved a higher iPSC generation efficiency than the original retrovirus system[[48](#_ENREF_48)]. Successful reprogramming of somatic cells has also been achieved using microRNAs[[49](#_ENREF_49)], whereby expression of the *miR302/367* cluster containing five different miRNAs, *miR302a/b/c/d* and *miR367*, reprogrammed human fibroblasts more efficiently than previous retrovirus systems[[49](#_ENREF_49)]. Such RNA-based reprogramming avoids both breaks in existing genes and the reactivation of transgenes. Therefore, these methods hold much promise as novel iPSC generation methods that could be applicable for clinical use.

Similarly, recombinant proteins were also reported as a successful means of gene introduction for generating iPSCs[[50](#_ENREF_50),[51](#_ENREF_51)]. These protein-based methods are also attractive for clinical application because of the absence of breaks in existing host genes and the reactivation of transgenes; however, the generation efficiencies remain lower compared to those in the existing retrovirus systems[[50](#_ENREF_50),[51](#_ENREF_51)].

Finally, small-molecule drugs have been investigated for establishing safe methods of iPSC generation for clinical application because they are nonimmunogenic, cost-effective, and easy to handle[[52](#_ENREF_52)]. Recently, successful reprogramming of mouse somatic cells without transgene introduction was achieved with small-molecule drug combinations[[53](#_ENREF_53)]. This strategy has many merits for applying the iPSC generation method for clinical use, and therefore, further research into applying this method to human somatic cells is expected in the near future.

**TYPES OF DONOR CELLS FOR IPSC GENERATION**

Generating iPSCs in clinical practice also requires the consideration of the most appropriate type of donor cells. At first, iPSCs were generated from mouse fibroblasts[[1](#_ENREF_1)], followed by successful reprogramming of mouse hepatocytes and gastric epithelial cells[[54](#_ENREF_54)]. Subsequently, terminally differentiated somatic cells have also been reprogrammed, including mouse B lymphocytes[[55](#_ENREF_55)] and pancreatic beta cells[[56](#_ENREF_56)]. With respect to human cells, iPSCs have been generated from human dermal fibroblasts[[2](#_ENREF_2),[10](#_ENREF_10)] and many types of human somatic cells[5].

As a matter of course, clinical applications of cell therapies require that tissue collection from patients be as minimally invasive as possible, and harvesting human dermal fibroblasts by biopsy leaves a small scar on the patient’s body. Recently, iPSCs were generated from human keratinocytes induced from plucked hair, a process that is much less invasive than biopsy[[23](#_ENREF_23),[57](#_ENREF_57)]. However, several hairs are needed to obtain the successful cell outgrowth of keratinocytes in some cases, and therefore, a more stable protocol for primary culture is needed for routine clinical practice.

Dental tissue has also been proposed as a unique cell source for iPSC generation. Dental stem cells[[58](#_ENREF_58),[59](#_ENREF_59)] and mesenchymal stromal cells derived from human third molars[[60](#_ENREF_60)] were successfully reprogrammed and thought to be potentially useful material for clinical iPSC generation. Oral gingival[[61](#_ENREF_61)] and oral mucosa fibroblasts[[62](#_ENREF_62)], which can be obtained less invasively, were also investigated for iPSC generation. These methods are advantageous for clinical application because they involve a minimally invasive approach for the patients.

Cord blood was also reported as another cell source for generating iPSCs[[63](#_ENREF_63),[64](#_ENREF_64)]. Early studies with cord blood yielded lower reprogramming efficiencies than those achieved with lentivirus or retrovirus systems. However, a modified method involving the knockout of p53, which was previously shown to increase the efficiency of reprogramming[[65-70](#_ENREF_65)] for iPSCs, increased the efficiency of generating iPSCs from CD34-positive cells which were sorted from cord blood cells[[71](#_ENREF_71)]. Additionally, gene introduction using Sendai virus vectors successfully reprogrammed CD34-positive cord blood cells more efficiently than lentiviral or retroviral vector used to reprogram cord blood cells[[36](#_ENREF_36)]. Cord blood cells have attracted much attention because cord blood-derived cells do not require laborious mobilization or an invasive biopsy before introducing reprogramming factors. Using cord blood cells for iPSC generation also avoids the risk of transreeing over accumulated genetic mutations into iPSC. Additionally, banked cord blood cells are relatively uncomplicated for use in iPSC generation because their immunological information is already available in cord blood banks[[72](#_ENREF_72)].

Peripheral blood cells are also an attractive cell source because the method for cell sampling from patients is less invasive. Peripheral blood cells are more easily accessible as a cell source than the dermal fibroblasts obtained by skin biopsy. In the first study to generate iPSCs from human blood cells, the donor needed to be injected for 3 days with G-CSF to mobilize the CD34-positive cells, and the reprogramming efficiency was not higher than that of previous studies[[73](#_ENREF_73)]; however, since then there have been many efforts to effectively generate iPSCs from peripheral blood cells. For example, less invasive methods have since been reported for generating iPSCs from peripheral mononuclear blood cells[[34](#_ENREF_34),[74-77](#_ENREF_74)], whereby mononuclear blood cells from donors or frozen samples were induced using the Yamanaka factors with a retrovirus[[74](#_ENREF_74),[77](#_ENREF_77)], lentivirus[[75](#_ENREF_75),[76](#_ENREF_76)], or Sendai virus[[34](#_ENREF_34)]. In these experiments, the majority of iPSCs generated from mononuclear cells had *TCR* gene rearrangements, indicating that these cell lines were derived from T lymphocytes, and the reprogramming efficiencies with the Sendai virus were similar to those with the previous retrovirus system[[34](#_ENREF_34)]. Additionally, to avoid generating iPSCs containing genome rearrangements, methods were developed in which iPSCs were generated from peripheral mononuclear cells cultured under conditions that inhibit the proliferation of lymphocytes[[78](#_ENREF_78),[79](#_ENREF_79)] and from CD34-positive cells that were mobilized without additional drug administration to the donors[[80](#_ENREF_80)]. Sampling of peripheral blood is one of the least invasive procedures available, and therefore, generating iPSCs from peripheral blood could be one of the most appropriate methods for the clinical applications of iPSCs.

**REMOVING ANIMAL PRODUCTS FROM CULTURE SYSTEMS**

One of the most important issues to address in applying iPSCs to clinical therapy is that the culture systems for generating iPSCs contain animal-derived products with potential and unpredictable risks to patients[[81](#_ENREF_81)]. The initial culture system for ESC generation contained fetal calf serum in the culture medium and mouse embryonic ﬁbroblasts (MEF) as a feeder layer. These animal-derived products conferred a risk of transferring exogenous antigens, unknown viruses, or zoonotic pathogens to the generated cell populations [[9](#_ENREF_9)]. Thus, many investigations have be conducted to reduce such risks by establishing animal product-free culture systems for human iPSCs.

First, human-derived feeder cells have proven to be a useful alternative to mouse cells for human iPSC generation[[82](#_ENREF_82)]. However, these feeder cell preparations need significant time and effort, and in the case of clinical therapies requiring the mass culture of human iPSCs in some situations, using human-derived feeder cells for culturing human iPSCs is not an optimal strategy. As an option for culturing human iPSCs without feeder cells, Matrigel has proven to be a useful alternative that enables the stable culture of human pluripotent stem cells[[83-85](#_ENREF_83)]. Although Matrigel allows the generation of human iPSCs without animal-derived feeder cells[[86](#_ENREF_86),[87](#_ENREF_87)], Matrigel itself was derived from Engelbreth-Holm-Swarm mouse sarcoma cells[[88](#_ENREF_88)]. Therefore, other types of matrices, such as CellStart[[89](#_ENREF_89),[90](#_ENREF_90)], recombinant proteins[[91-93](#_ENREF_91)], and synthetic polymers[[94](#_ENREF_94),[95](#_ENREF_95)], which do not contain animal-derived agents, have been tested and used as feeder-cell substitutes for the successful maintenance and generation of human pluripotent cells.

Developing animal product-free medium for iPSC generation is also an important practice for achieving safe therapy using iPSCs. The culture media used in the early generation of human ESCs contained fetal bovine serum[[9](#_ENREF_9)]. To remove unpredictable agents that might cause the differentiation of human ESCs, knockout serum replacement (KSR) has now been established as a defined material for maintaining human ESCs[[96](#_ENREF_96)] and is also used for human iPSC generation[[2](#_ENREF_2)]. Additionally, mTeSR1 medium was developed as a chemically defined medium for maintaining human pluripotent cells and is used for defined condition cultures of human pluripotent stem cells[[97](#_ENREF_97)]. However, because KSR and mTeSR1 also contain animal-derived products, new media have now been commercially developed as xeno-free media for maintaining human pluripotent stem cells and have already been used successfully for iPSC generation; these media include TeSR2[[98](#_ENREF_98)], NutriStem[[99](#_ENREF_99)], Essential E8[[91](#_ENREF_91)], and StemFit [[100](#_ENREF_100)].

**SELECTING THE MOST APPROPRIATE IPSC LINE FOR CLINICAL USE**

One of the most intractable problems for applying iPSCs to clinical therapy is the variety of iPSC lines with respect to differentiation tendency and tumorigenic risk. Additionally, the laboratory in which the iPSCs are generated could influence global gene expression patterns of those iPSCs due to small possible differences in the culture conditions[[101](#_ENREF_101)]. Therefore, how to select iPSC lines that are appropriate for a specific clinical use in terms of safety and differentiation ability remains a topic of intense discussion.

As described above, in contrast to generating iPSCs with Yamanaka factors, introducing *TBX3*[[14](#_ENREF_14)], *L-MYC*[[15](#_ENREF_15)], or *GLIS1*[[16](#_ENREF_16)] instead of *C-MYC* has yielded high-quality iPSCs with respect to the efficiency of germ line transmission and prognosis of iPSC-derived mouse cells. These reports implied that selecting suitable combinations of reprogramming factors was an important consideration for clinical therapy using iPSCs. However, these reports were derived from mouse experiments, and how these findings translate to human iPSCs remains unknown. Of course, the quality index of iPSCs using chimeric formation is not applicable to human iPSCs. Therefore, another index of iPSC quality that is applicable to human iPSCs is required.

With respect to assessing the effects of the type of donor cell on the quality of generated iPSCs, the teratoma-forming propensity of neural stem and progenitor cells derived from mouse iPSCs was shown to differ depending on the donor cell type[[102](#_ENREF_102)]. This finding suggested that the quality of the iPSCs should be considered when the type of donor cell is selected. Since that early report, an epigenetic memory of tissue of origin donor cell type that affected the differentiation tendency of iPSCs was reported[[103](#_ENREF_103),[104](#_ENREF_104)]. Importantly, the effect of epigenetic memory was not demonstrated when pluripotent stem cells generated by nuclear transfer were used. Additionally, another recent study showed that human iPSCs contain more CpG sites that retain the DNA methylation pattern of the parental donor cells than human ESCs generated by nuclear transfer[[105](#_ENREF_105)]. Although the fact that the differentiation tendency derived from epigenetic memory will not remain after long-term culture[[103](#_ENREF_103)], these reports also suggested the importance of selecting the donor cell type when applying iPSCs clinically.

The effect of donor cell type on differentiation tendency was also reported in human iPSCs[[106](#_ENREF_106)], but experiments that compared donor cell type, gene vehicle type, and volunteers on hepatic differentiation tendencies of iPSCs showed that the differentiation tendency of iPSCs depended on the volunteer from which the iPSCs were generated[[107](#_ENREF_107)]. Interestingly, in this latter study, hepatic differentiation tendencies that were derived from donor cells were not observed, implying that such differences derive from the volunteer cell donor when epigenetic memory does not remain after long-term culture.

With respect to the tumorigenic tendencies of human iPSCs, a study of gene expression and DNA methylation in 21 human iPSC lines and 2 human ESC lines showed activated expression of genes containing specific LTR7 sequences in some human iPSC clones that showed a neural differentiation-defective phenotype and formation of teratomas when they were differentiated into dopaminergic neurons and transplanted in mouse brains[[108](#_ENREF_108)]. Another report on 21 human iPSC lines and 6 human ESC lines indicated that certain human iPSC clones were in a pro-oncogenic state, as shown by the ectopic presence of secretory tumor tissue during in vitro cartilage differentiation[[109](#_ENREF_109)]. These reports together implied that a marker foreseeing pro-oncogenic differences in iPSC lines would be required for establishing safe therapy using iPSCs.

**AUTO-TRANSPLANTATION AND ALLO-TRANSPLANTATION OF IPSCS**

One of the most important advantages expected of iPSCs for transplantation therapy is avoiding immune rejection and therefore avoiding combination immunosuppressive treatment. Indeed, autologous iPSCs were used in the first human clinical trial of iPSCs started by Dr. Masayo Takahashi at the RIKEN Center for Developmental Biology in Kobe in 2013 for treating age-related macular degeneration with iPSC-derived sheets of retinal pigment epithelium. With respect to the immunogenicity of autologous iPSCs, in the first report that aroused discussion on its credibility, immunogenicity showed in the case of iPSCs was not observed in the case of ESCs[[110](#_ENREF_110),[111](#_ENREF_111)]. Subsequently, experiments with isogenic transplantation of mouse iPSCs revealed the successful engraftment of iPSC-derived tissue without immunosuppressive treatment and verified the advantages of using auto-transplantation of iPSCs for avoiding immunosuppressive treatment[[112](#_ENREF_112),[113](#_ENREF_113)]. However, a recent study demonstrated immune rejection upon transplanting autologous undifferentiated mouse iPSCs in vivo, and rejection was imperceptible upon transplanting autologous terminally differentiated mouse iPSCs[[114](#_ENREF_114)]. Although this report supports the presence of immunogenicity in undifferentiated iPSCs [91] and conflicts with the successful autologous engraftment of undifferentiated iPSCs in other reports[93,94], it supports the advantages of using auto-transplantation of iPSC-derived terminally differentiated cells for avoiding immunosuppressive treatment. On another front, whether the immunogenicity in undifferentiated iPSCs contributes to removing contaminated undifferentiated cells from iPSC-derived cell populations and avoiding tumorigenesis after transplantation in the same manner as removing undifferentiated cells from cell populations before transplantation[[115-117](#_ENREF_115)] remains to be clarified.

Allo-transplantation of iPSC-derived cells was also expected to provide a useful strategy for transplantation therapy using iPSCs due to saving cost and time in generating autologous iPSC lines for transplantation. Furthermore, as described above, selecting appropriate iPSC lines on a patient-by-patient basis will require significant numbers of studies for verification. Therefore, although the transplantation of iPSC-derived cells from an allogenic donor with foreign HLA requires lifelong immunosuppressive treatment of the recipient, the concept of homozygous HLA-typed iPSC banks may be feasible for achieving generalized therapy using iPSCs[[41](#_ENREF_41),[118](#_ENREF_118),[119](#_ENREF_119)] and, indeed, this type of approach is already progressing[[120](#_ENREF_120)].

**CONCLUSION**

The invention of iPSCs was groundbreaking for novel regenerative medicine and has been expected to lead to regenerative therapies with the potential to advance the treatment and management of incurable diseases. Importantly, iPSCs could overcome the problems of immune rejection and ethics that remain with ESCs. However, each strategy of using autologous or allogenic iPSCs has advantages and disadvantages, and the choice of appropriate strategy may vary depending on the intended use. Additionally, there remain many factors that affect establishing transplantation therapy using iPSCs. To avoid tumorigenesis and establish effective differentiation into the intended cells, further investigation is needed to clarify which iPSC line is the most suitable and how these lines can be best selected.

**REFERENCES**

1 **Takahashi K**, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell* 2006; **126**: 663-676 [PMID: 16904174 DOI: 10.1016/j.cell.2006.07.024]

2 **Takahashi K**, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell* 2007; **131**: 861-872 [PMID: 18035408 DOI: 10.1016/j.cell.2007.11.019]

3 **Nakamura M**, Okano H. Cell transplantation therapies for spinal cord injury focusing on induced pluripotent stem cells. *Cell Res* 2013; **23**: 70-80 [PMID: 23229514 DOI: 10.1038/cr.2012.171]

4 **Ross CA**, Akimov SS. Human-induced pluripotent stem cells: potential for neurodegenerative diseases. *Hum Mol Genet* 2014; **23**: R17-R26 [PMID: 24824217 DOI: 10.1093/hmg/ddu204]

5 **Fujita J**, Itabashi Y, Seki T, Tohyama S, Tamura Y, Sano M, Fukuda K. Myocardial cell sheet therapy and cardiac function. *Am J Physiol Heart Circ Physiol* 2012; **303**: H1169-H1182 [PMID: 23001836 DOI: 10.1152/ajpheart.00376.2012]

6 **Hsiao LC,** Carr C, Chang KC, Lin SZ, Clarke K. Stem cell-based therapy for ischemic heart disease. *Cell Transplant* 2013; **22:** 663-675 [PMID: 23044395 DOI: 10.3727/096368912x655109]

7 **Holditch SJ**, Terzic A, Ikeda Y. Concise review: pluripotent stem cell-based regenerative applications for failing β-cell function. *Stem Cells Transl Med* 2014; **3**: 653-661 [PMID: 24646490 DOI: 10.5966/sctm.2013-0184]

8 **Ramsden CM,** Powner MB, Carr AJ, Smart MJ, da Cruz L, Coffey PJ. Stem cells in retinal regeneration: Past, present and future. *Development* 2013; **140:** 2576-2585 [PMID: 23715550 DOI: 10.1242/dev.092270]

9 **Thomson JA,** Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, Jones JM. Embryonic stem cell lines derived from human blastocysts. *Science* 1998; **282:** 1145-1147 [PMID: 9804556 DOI: 10.1126/science.282.5391.1145]

10 **Yu J**, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Nie J, Jonsdottir GA, Ruotti V, Stewart R, Slukvin II, Thomson JA. Induced pluripotent stem cell lines derived from human somatic cells. *Science* 2007; **318**: 1917-1920 [PMID: 18029452 DOI: 10.1126/science.1151526]

11 **Tomohisa S,** Yuasa S. Human iPS cell generation methods for clinical usage*.* California: CRC Press LLC, 2013: 20-34

12 **Wernig M**, Meissner A, Cassady JP, Jaenisch R. c-Myc is dispensable for direct reprogramming of mouse fibroblasts. *Cell Stem Cell* 2008; **2**: 10-12 [PMID: 18371415 DOI: 10.1016/j.stem.2007.12.001]

13 **Nakagawa M**, Koyanagi M, Tanabe K, Takahashi K, Ichisaka T, Aoi T, Okita K, Mochiduki Y, Takizawa N, Yamanaka S. Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. *Nat Biotechnol* 2008; **26**: 101-106 [PMID: 18059259 DOI: 10.1038/nbt1374]

14 **Han J**, Yuan P, Yang H, Zhang J, Soh BS, Li P, Lim SL, Cao S, Tay J, Orlov YL, Lufkin T, Ng HH, Tam WL, Lim B. Tbx3 improves the germ-line competency of induced pluripotent stem cells. *Nature* 2010; **463**: 1096-1100 [PMID: 20139965 DOI: 10.1038/nature08735]

15 **Nakagawa M**, Takizawa N, Narita M, Ichisaka T, Yamanaka S. Promotion of direct reprogramming by transformation-deficient Myc. *Proc Natl Acad Sci U S A* 2010; **107**: 14152-14157 [PMID: 20660764 DOI: 10.1073/pnas.1009374107]

16 **Maekawa M**, Yamaguchi K, Nakamura T, Shibukawa R, Kodanaka I, Ichisaka T, Kawamura Y, Mochizuki H, Goshima N, Yamanaka S. Direct reprogramming of somatic cells is promoted by maternal transcription factor Glis1. *Nature* 2011; **474**: 225-229 [PMID: 21654807 DOI: 10.1038/nature10106]

17 **Jiang J**, Lv W, Ye X, Wang L, Zhang M, Yang H, Okuka M, Zhou C, Zhang X, Liu L, Li J. Zscan4 promotes genomic stability during reprogramming and dramatically improves the quality of iPS cells as demonstrated by tetraploid complementation. *Cell Res* 2013; **23**: 92-106 [PMID: 23147797 DOI: 10.1038/cr.2012.157]

18 **Montserrat N**, Nivet E, Sancho-Martinez I, Hishida T, Kumar S, Miquel L, Cortina C, Hishida Y, Xia Y, Esteban CR, Izpisua Belmonte JC. Reprogramming of human fibroblasts to pluripotency with lineage specifiers. *Cell Stem Cell* 2013; **13**: 341-350 [PMID: 23871606 DOI: 10.1016/j.stem.2013.06.019]

19 **Takahashi K**, Okita K, Nakagawa M, Yamanaka S. Induction of pluripotent stem cells from fibroblast cultures. *Nat Protoc* 2007; **2**: 3081-3089 [PMID: 18079707 DOI: 10.1038/nprot.2007.418]

20 **Kitamura T,** Koshino Y, Shibata F, Oki T, Nakajima H, Nosaka T, Kumagai H. Retrovirus-mediated gene transfer and expression cloning: Powerful tools in functional genomics. *Exp Hematol* 2003; **31:** 1007-1014 [PMID: 14585362 DOI: 10.1016/j.exphem.2003.07.005]

21 **Wernig M**, Meissner A, Foreman R, Brambrink T, Ku M, Hochedlinger K, Bernstein BE, Jaenisch R. In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. *Nature* 2007; **448**: 318-324 [PMID: 17554336 DOI: 10.1038/nature05944]

22 **Hawley RG**, Lieu FH, Fong AZ, Hawley TS. Versatile retroviral vectors for potential use in gene therapy. *Gene Ther* 1994; **1**: 136-138 [PMID: 7584069]

23 **Aasen T**, Raya A, Barrero MJ, Garreta E, Consiglio A, Gonzalez F, Vassena R, Bilić J, Pekarik V, Tiscornia G, Edel M, Boué S, Izpisúa Belmonte JC. Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes. *Nat Biotechnol* 2008; **26**: 1276-1284 [PMID: 18931654 DOI: 10.1038/nbt.1503]

24 **Jähner D**, Stuhlmann H, Stewart CL, Harbers K, Löhler J, Simon I, Jaenisch R. De novo methylation and expression of retroviral genomes during mouse embryogenesis. *Nature* 1982; **298**: 623-628 [PMID: 6285203]

25 **Hotta A**, Ellis J. Retroviral vector silencing during iPS cell induction: an epigenetic beacon that signals distinct pluripotent states. *J Cell Biochem* 2008; **105**: 940-948 [PMID: 18773452 DOI: 10.1002/jcb.21912]

26 **Blelloch R**, Venere M, Yen J, Ramalho-Santos M. Generation of induced pluripotent stem cells in the absence of drug selection. *Cell Stem Cell* 2007; **1**: 245-247 [PMID: 18371358 DOI: 10.1016/j.stem.2007.08.008]

27 **Yao S**, Sukonnik T, Kean T, Bharadwaj RR, Pasceri P, Ellis J. Retrovirus silencing, variegation, extinction, and memory are controlled by a dynamic interplay of multiple epigenetic modifications. *Mol Ther* 2004; **10**: 27-36 [PMID: 15233939 DOI: 10.1016/j.ymthe.2004.04.007]

28 **Okita K**, Ichisaka T, Yamanaka S. Generation of germline-competent induced pluripotent stem cells. *Nature* 2007; **448**: 313-317 [PMID: 17554338 DOI: 10.1038/nature05934]

29 **Stadtfeld M**, Nagaya M, Utikal J, Weir G, Hochedlinger K. Induced pluripotent stem cells generated without viral integration. *Science* 2008; **322**: 945-949 [PMID: 18818365 DOI: 10.1126/science.1162494]

30 **Harui A**, Suzuki S, Kochanek S, Mitani K. Frequency and stability of chromosomal integration of adenovirus vectors. *J Virol* 1999; **73**: 6141-6146 [PMID: 10364373]

31 **Hanna J**, Wernig M, Markoulaki S, Sun CW, Meissner A, Cassady JP, Beard C, Brambrink T, Wu LC, Townes TM, Jaenisch R. Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. *Science* 2007; **318**: 1920-1923 [PMID: 18063756 DOI: 10.1126/science.1152092]

32 **Nagy A.** Cre recombinase: The universal reagent for genome tailoring. *Genesis* 2000; **26:** 99-109 [PMID: 10686599]

33 **Fusaki N**, Ban H, Nishiyama A, Saeki K, Hasegawa M. Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome. *Proc Jpn Acad Ser B Phys Biol Sci* 2009; **85**: 348-362 [PMID: 19838014 DOI: 10.2183/pjab.85.348]

34 **Seki T**, Yuasa S, Oda M, Egashira T, Yae K, Kusumoto D, Nakata H, Tohyama S, Hashimoto H, Kodaira M, Okada Y, Seimiya H, Fusaki N, Hasegawa M, Fukuda K. Generation of induced pluripotent stem cells from human terminally differentiated circulating T cells. *Cell Stem Cell* 2010; **7**: 11-14 [PMID: 20621043 DOI: 10.1016/j.stem.2010.06.003]

35 **Nishimura K**, Sano M, Ohtaka M, Furuta B, Umemura Y, Nakajima Y, Ikehara Y, Kobayashi T, Segawa H, Takayasu S, Sato H, Motomura K, Uchida E, Kanayasu-Toyoda T, Asashima M, Nakauchi H, Yamaguchi T, Nakanishi M. Development of defective and persistent Sendai virus vector: a unique gene delivery/expression system ideal for cell reprogramming. *J Biol Chem* 2011; **286**: 4760-4771 [PMID: 21138846 DOI: 10.1074/jbc.M110.183780]

36 **Ban H**, Nishishita N, Fusaki N, Tabata T, Saeki K, Shikamura M, Takada N, Inoue M, Hasegawa M, Kawamata S, Nishikawa S. Efficient generation of transgene-free human induced pluripotent stem cells (iPSCs) by temperature-sensitive Sendai virus vectors. *Proc Natl Acad Sci U S A* 2011; **108**: 14234-14239 [PMID: 21821793 DOI: 10.1073/pnas.1103509108]

37 **Jia F**, Wilson KD, Sun N, Gupta DM, Huang M, Li Z, Panetta NJ, Chen ZY, Robbins RC, Kay MA, Longaker MT, Wu JC. A nonviral minicircle vector for deriving human iPS cells. *Nat Methods* 2010; **7**: 197-199 [PMID: 20139967 DOI: 10.1038/nmeth.1426]

38 **Gonzalez F**, Barragan Monasterio M, Tiscornia G, Montserrat Pulido N, Vassena R, Batlle Morera L, Rodriguez Piza I, Izpisua Belmonte JC. Generation of mouse-induced pluripotent stem cells by transient expression of a single nonviral polycistronic vector. *Proc Natl Acad Sci U S A* 2009; **106**: 8918-8922 [PMID: 19458047 DOI: 10.1073/pnas.0901471106]

39 **Yu J**, Hu K, Smuga-Otto K, Tian S, Stewart R, Slukvin II, Thomson JA. Human induced pluripotent stem cells free of vector and transgene sequences. *Science* 2009; **324**: 797-801 [PMID: 19325077 DOI: 10.1126/science.1172482]

40 **Okita K**, Nakagawa M, Hyenjong H, Ichisaka T, Yamanaka S. Generation of mouse induced pluripotent stem cells without viral vectors. *Science* 2008; **322**: 949-953 [PMID: 18845712 DOI: 10.1126/science.1164270]

41 **Okita K**, Matsumura Y, Sato Y, Okada A, Morizane A, Okamoto S, Hong H, Nakagawa M, Tanabe K, Tezuka K, Shibata T, Kunisada T, Takahashi M, Takahashi J, Saji H, Yamanaka S. A more efficient method to generate integration-free human iPS cells. *Nat Methods* 2011; **8**: 409-412 [PMID: 21460823 DOI: 10.1038/nmeth.1591]

42 **Okita K**, Yamakawa T, Matsumura Y, Sato Y, Amano N, Watanabe A, Goshima N, Yamanaka S. An efficient nonviral method to generate integration-free human-induced pluripotent stem cells from cord blood and peripheral blood cells. *Stem Cells* 2013; **31**: 458-466 [PMID: 23193063 DOI: 10.1002/stem.1293]

43 **Yusa K**, Rad R, Takeda J, Bradley A. Generation of transgene-free induced pluripotent mouse stem cells by the piggyBac transposon. *Nat Methods* 2009; **6**: 363-369 [PMID: 19337237 DOI: 10.1038/nmeth.1323]

44 **Kaji K**, Norrby K, Paca A, Mileikovsky M, Mohseni P, Woltjen K. Virus-free induction of pluripotency and subsequent excision of reprogramming factors. *Nature* 2009; **458**: 771-775 [PMID: 19252477 DOI: 10.1038/nature07864]

45 **Woltjen K**, Michael IP, Mohseni P, Desai R, Mileikovsky M, Hämäläinen R, Cowling R, Wang W, Liu P, Gertsenstein M, Kaji K, Sung HK, Nagy A. piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. *Nature* 2009; **458**: 766-770 [PMID: 19252478 DOI: 10.1038/nature07863]

46 **Cary LC,** Goebel M, Corsaro BG, Wang HG, Rosen E, Fraser MJ. Transposon mutagenesis of baculoviruses: Analysis of trichoplusia ni transposon IFP2 insertions within the FP-locus of nuclear polyhedrosis viruses. *Virology* 1989; **172:** 156-169 [PMID: 2549707]

47 **Ding S**, Wu X, Li G, Han M, Zhuang Y, Xu T. Efficient transposition of the piggyBac (PB) transposon in mammalian cells and mice. *Cell* 2005; **122**: 473-483 [PMID: 16096065 DOI: 10.1016/j.cell.2005.07.013]

48 **Warren L**, Manos PD, Ahfeldt T, Loh YH, Li H, Lau F, Ebina W, Mandal PK, Smith ZD, Meissner A, Daley GQ, Brack AS, Collins JJ, Cowan C, Schlaeger TM, Rossi DJ. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. *Cell Stem Cell* 2010; **7**: 618-630 [PMID: 20888316 DOI: 10.1016/j.stem.2010.08.012]

49 **Anokye-Danso F**, Trivedi CM, Juhr D, Gupta M, Cui Z, Tian Y, Zhang Y, Yang W, Gruber PJ, Epstein JA, Morrisey EE. Highly efficient miRNA-mediated reprogramming of mouse and human somatic cells to pluripotency. *Cell Stem Cell* 2011; **8**: 376-388 [PMID: 21474102 DOI: 10.1016/j.stem.2011.03.001]

50 **Zhou H**, Wu S, Joo JY, Zhu S, Han DW, Lin T, Trauger S, Bien G, Yao S, Zhu Y, Siuzdak G, Schöler HR, Duan L, Ding S. Generation of induced pluripotent stem cells using recombinant proteins. *Cell Stem Cell* 2009; **4**: 381-384 [PMID: 19398399 DOI: 10.1016/j.stem.2009.04.005]

51 **Kim D**, Kim CH, Moon JI, Chung YG, Chang MY, Han BS, Ko S, Yang E, Cha KY, Lanza R, Kim KS. Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. *Cell Stem Cell* 2009; **4**: 472-476 [PMID: 19481515 DOI: 10.1016/j.stem.2009.05.005]

52 **Zhang R**, Zhang LH, Xie X. iPSCs and small molecules: a reciprocal effort towards better approaches for drug discovery. *Acta Pharmacol Sin* 2013; **34**: 765-776 [PMID: 23603980 DOI: 10.1038/aps.2013.21]

53 **Hou P**, Li Y, Zhang X, Liu C, Guan J, Li H, Zhao T, Ye J, Yang W, Liu K, Ge J, Xu J, Zhang Q, Zhao Y, Deng H. Pluripotent stem cells induced from mouse somatic cells by small-molecule compounds. *Science* 2013; **341**: 651-654 [PMID: 23868920 DOI: 10.1126/science.1239278]

54 **Aoi T**, Yae K, Nakagawa M, Ichisaka T, Okita K, Takahashi K, Chiba T, Yamanaka S. Generation of pluripotent stem cells from adult mouse liver and stomach cells. *Science* 2008; **321**: 699-702 [PMID: 18276851 DOI: 10.1126/science.1154884]

55 **Hanna J**, Markoulaki S, Schorderet P, Carey BW, Beard C, Wernig M, Creyghton MP, Steine EJ, Cassady JP, Foreman R, Lengner CJ, Dausman JA, Jaenisch R. Direct reprogramming of terminally differentiated mature B lymphocytes to pluripotency. *Cell* 2008; **133**: 250-264 [PMID: 18423197 DOI: 10.1016/j.cell.2008.03.028]

56 **Stadtfeld M**, Brennand K, Hochedlinger K. Reprogramming of pancreatic beta cells into induced pluripotent stem cells. *Curr Biol* 2008; **18**: 890-894 [PMID: 18501604 DOI: 10.1016/j.cub.2008.05.010]

57 **Aasen T,** Belmonte JC. Isolation and cultivation of human keratinocytes from skin or plucked hair for the generation of induced pluripotent stem cells. *Nat Protoc* 2010; **5:** 371-382 [PMID: 20134422 DOI: 10.1038/nprot.2009.241]

58 **Yan X**, Qin H, Qu C, Tuan RS, Shi S, Huang GT. iPS cells reprogrammed from human mesenchymal-like stem/progenitor cells of dental tissue origin. *Stem Cells Dev* 2010; **19**: 469-480 [PMID: 19795982 DOI: 10.1089/scd.2009.0314]

59 **Tamaoki N**, Takahashi K, Tanaka T, Ichisaka T, Aoki H, Takeda-Kawaguchi T, Iida K, Kunisada T, Shibata T, Yamanaka S, Tezuka K. Dental pulp cells for induced pluripotent stem cell banking. *J Dent Res* 2010; **89**: 773-778 [PMID: 20554890 DOI: 10.1177/0022034510366846]

60 **Oda Y**, Yoshimura Y, Ohnishi H, Tadokoro M, Katsube Y, Sasao M, Kubo Y, Hattori K, Saito S, Horimoto K, Yuba S, Ohgushi H. Induction of pluripotent stem cells from human third molar mesenchymal stromal cells. *J Biol Chem* 2010; **285**: 29270-29278 [PMID: 20595386 DOI: 10.1074/jbc.M109.055889]

61 **Egusa H**, Okita K, Kayashima H, Yu G, Fukuyasu S, Saeki M, Matsumoto T, Yamanaka S, Yatani H. Gingival fibroblasts as a promising source of induced pluripotent stem cells. *PLoS One* 2010; **5**: e12743 [PMID: 20856871 DOI: 10.1371/journal.pone.0012743]

62 **Miyoshi K,** Tsuji D, Kudoh K, Satomura K, Muto T, Itoh K, Noma T. Generation of human induced pluripotent stem cells from oral mucosa. *J Biosci Bioeng* 2010; **110:** 345-350 [PMID: 20547351 DOI: 10.1016/j.jbiosc.2010.03.004]

63 **Haase A**, Olmer R, Schwanke K, Wunderlich S, Merkert S, Hess C, Zweigerdt R, Gruh I, Meyer J, Wagner S, Maier LS, Han DW, Glage S, Miller K, Fischer P, Schöler HR, Martin U. Generation of induced pluripotent stem cells from human cord blood. *Cell Stem Cell* 2009; **5**: 434-441 [PMID: 19796623 DOI: 10.1016/j.stem.2009.08.021]

64 **Giorgetti A**, Montserrat N, Aasen T, Gonzalez F, Rodríguez-Pizà I, Vassena R, Raya A, Boué S, Barrero MJ, Corbella BA, Torrabadella M, Veiga A, Izpisua Belmonte JC. Generation of induced pluripotent stem cells from human cord blood using OCT4 and SOX2. *Cell Stem Cell* 2009; **5**: 353-357 [PMID: 19796614 DOI: 10.1016/j.stem.2009.09.008]

65 **Zhao Y**, Yin X, Qin H, Zhu F, Liu H, Yang W, Zhang Q, Xiang C, Hou P, Song Z, Liu Y, Yong J, Zhang P, Cai J, Liu M, Li H, Li Y, Qu X, Cui K, Zhang W, Xiang T, Wu Y, Zhao Y, Liu C, Yu C, Yuan K, Lou J, Ding M, Deng H. Two supporting factors greatly improve the efficiency of human iPSC generation. *Cell Stem Cell* 2008; **3**: 475-479 [PMID: 18983962 DOI: 10.1016/j.stem.2008.10.002]

66 **Utikal J**, Polo JM, Stadtfeld M, Maherali N, Kulalert W, Walsh RM, Khalil A, Rheinwald JG, Hochedlinger K. Immortalization eliminates a roadblock during cellular reprogramming into iPS cells. *Nature* 2009; **460**: 1145-1148 [PMID: 19668190 DOI: 10.1038/nature08285]

67 **Marión RM**, Strati K, Li H, Murga M, Blanco R, Ortega S, Fernandez-Capetillo O, Serrano M, Blasco MA. A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity. *Nature* 2009; **460**: 1149-1153 [PMID: 19668189 DOI: 10.1038/nature08287]

68 **Li H**, Collado M, Villasante A, Strati K, Ortega S, Cañamero M, Blasco MA, Serrano M. The Ink4/Arf locus is a barrier for iPS cell reprogramming. *Nature* 2009; **460**: 1136-1139 [PMID: 19668188 DOI: 10.1038/nature08290]

69 **Kawamura T**, Suzuki J, Wang YV, Menendez S, Morera LB, Raya A, Wahl GM, Izpisúa Belmonte JC. Linking the p53 tumour suppressor pathway to somatic cell reprogramming. *Nature* 2009; **460**: 1140-1144 [PMID: 19668186 DOI: 10.1038/nature08311]

70 **Hong H**, Takahashi K, Ichisaka T, Aoi T, Kanagawa O, Nakagawa M, Okita K, Yamanaka S. Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. *Nature* 2009; **460**: 1132-1135 [PMID: 19668191 DOI: 10.1038/nature08235]

71 **Takenaka C**, Nishishita N, Takada N, Jakt LM, Kawamata S. Effective generation of iPS cells from CD34+ cord blood cells by inhibition of p53. *Exp Hematol* 2010; **38**: 154-162 [PMID: 19922768 DOI: 10.1016/j.exphem.2009.11.003]

72 **Gluckman E**, Rocha V. Cord blood transplantation: state of the art. *Haematologica* 2009; **94**: 451-454 [PMID: 19336748 DOI: 10.3324/haematol.2009.005694]

73 **Loh YH**, Agarwal S, Park IH, Urbach A, Huo H, Heffner GC, Kim K, Miller JD, Ng K, Daley GQ. Generation of induced pluripotent stem cells from human blood. *Blood* 2009; **113**: 5476-5479 [PMID: 19299331 DOI: 10.1182/blood-2009-02-204800]

74 **Brown ME**, Rondon E, Rajesh D, Mack A, Lewis R, Feng X, Zitur LJ, Learish RD, Nuwaysir EF. Derivation of induced pluripotent stem cells from human peripheral blood T lymphocytes. *PLoS One* 2010; **5**: e11373 [PMID: 20617191 DOI: 10.1371/journal.pone.0011373]

75 **Loh YH**, Hartung O, Li H, Guo C, Sahalie JM, Manos PD, Urbach A, Heffner GC, Grskovic M, Vigneault F, Lensch MW, Park IH, Agarwal S, Church GM, Collins JJ, Irion S, Daley GQ. Reprogramming of T cells from human peripheral blood. *Cell Stem Cell* 2010; **7**: 15-19 [PMID: 20621044 DOI: 10.1016/j.stem.2010.06.004]

76 **Staerk J**, Dawlaty MM, Gao Q, Maetzel D, Hanna J, Sommer CA, Mostoslavsky G, Jaenisch R. Reprogramming of human peripheral blood cells to induced pluripotent stem cells. *Cell Stem Cell* 2010; **7**: 20-24 [PMID: 20621045 DOI: 10.1016/j.stem.2010.06.002]

77 **Kunisato A**, Wakatsuki M, Shinba H, Ota T, Ishida I, Nagao K. Direct generation of induced pluripotent stem cells from human nonmobilized blood. *Stem Cells Dev* 2011; **20**: 159-168 [PMID: 20497033 DOI: 10.1089/scd.2010.0063]

78 **Chou BK**, Mali P, Huang X, Ye Z, Dowey SN, Resar LM, Zou C, Zhang YA, Tong J, Cheng L. Efficient human iPS cell derivation by a non-integrating plasmid from blood cells with unique epigenetic and gene expression signatures. *Cell Res* 2011; **21**: 518-529 [PMID: 21243013 DOI: 10.1038/cr.2011.12]

79 **Dowey SN**, Huang X, Chou BK, Ye Z, Cheng L. Generation of integration-free human induced pluripotent stem cells from postnatal blood mononuclear cells by plasmid vector expression. *Nat Protoc* 2012; **7**: 2013-2021 [PMID: 23080273 DOI: 10.1038/nprot.2012.121]

80 **Merling RK**, Sweeney CL, Choi U, De Ravin SS, Myers TG, Otaizo-Carrasquero F, Pan J, Linton G, Chen L, Koontz S, Theobald NL, Malech HL. Transgene-free iPSCs generated from small volume peripheral blood nonmobilized CD34+ cells. *Blood* 2013; **121**: e98-107 [PMID: 23386128 DOI: 10.1182/blood-2012-03-420273]

81 **Sampsell-Barron T**. Xeno-free adaptation and culture of human pluripotent stem cells. *Methods Mol Biol* 2013; **1001**: 81-97 [PMID: 23494422 DOI: 10.1007/978-1-62703-363-3\_8]

82 **Takahashi K**, Narita M, Yokura M, Ichisaka T, Yamanaka S. Human induced pluripotent stem cells on autologous feeders. *PLoS One* 2009; **4**: e8067 [PMID: 19956543 DOI: 10.1371/journal.pone.0008067]

83 **Totonchi M**, Taei A, Seifinejad A, Tabebordbar M, Rassouli H, Farrokhi A, Gourabi H, Aghdami N, Hosseini-Salekdeh G, Baharvand H. Feeder- and serum-free establishment and expansion of human induced pluripotent stem cells. *Int J Dev Biol* 2010; **54**: 877-886 [PMID: 19876814 DOI: 10.1387/ijdb.092903mt]

84 **Stover AE**, Schwartz PH. Adaptation of human pluripotent stem cells to feeder-free conditions in chemically defined medium with enzymatic single-cell passaging. *Methods Mol Biol* 2011; **767**: 137-146 [PMID: 21822872 DOI: 10.1007/978-1-61779-201-4\_10]

85 **Xu C**, Inokuma MS, Denham J, Golds K, Kundu P, Gold JD, Carpenter MK. Feeder-free growth of undifferentiated human embryonic stem cells. *Nat Biotechnol* 2001; **19**: 971-974 [PMID: 11581665 DOI: 10.1038/nbt1001-971]

86 **Kishino Y**, Seki T, Fujita J, Yuasa S, Tohyama S, Kunitomi A, Tabei R, Nakajima K, Okada M, Hirano A, Kanazawa H, Fukuda K. Derivation of transgene-free human induced pluripotent stem cells from human peripheral T cells in defined culture conditions. *PLoS One* 2014; **9**: e97397 [PMID: 24824994 DOI: 10.1371/journal.pone.0097397]

87 **Lai WH**, Ho JC, Lee YK, Ng KM, Au KW, Chan YC, Lau CP, Tse HF, Siu CW. ROCK inhibition facilitates the generation of human-induced pluripotent stem cells in a defined, feeder-, and serum-free system. *Cell Reprogram* 2010; **12**: 641-653 [PMID: 20858051 DOI: 10.1089/cell.2010.0051]

88 **Emonard H**, Grimaud JA, Nusgens B, Lapière CM, Foidart JM. Reconstituted basement-membrane matrix modulates fibroblast activities in vitro. *J Cell Physiol* 1987; **133**: 95-102 [PMID: 3667709 DOI: 10.1002/jcp.1041330112]

89 **Bergström R**, Ström S, Holm F, Feki A, Hovatta O. Xeno-free culture of human pluripotent stem cells. *Methods Mol Biol* 2011; **767**: 125-136 [PMID: 21822871 DOI: 10.1007/978-1-61779-201-4\_9]

90 **Ausubel LJ**, Lopez PM, Couture LA. GMP scale-up and banking of pluripotent stem cells for cellular therapy applications. *Methods Mol Biol* 2011; **767**: 147-159 [PMID: 21822873 DOI: 10.1007/978-1-61779-201-4\_11]

91 **Chen G**, Gulbranson DR, Hou Z, Bolin JM, Ruotti V, Probasco MD, Smuga-Otto K, Howden SE, Diol NR, Propson NE, Wagner R, Lee GO, Antosiewicz-Bourget J, Teng JM, Thomson JA. Chemically defined conditions for human iPSC derivation and culture. *Nat Methods* 2011; **8**: 424-429 [PMID: 21478862 DOI: 10.1038/nmeth.1593]

92 **Miyazaki T**, Futaki S, Suemori H, Taniguchi Y, Yamada M, Kawasaki M, Hayashi M, Kumagai H, Nakatsuji N, Sekiguchi K, Kawase E. Laminin E8 fragments support efficient adhesion and expansion of dissociated human pluripotent stem cells. *Nat Commun* 2012; **3**: 1236 [PMID: 23212365 DOI: 10.1038/ncomms2231]

93 **Rodin S**, Domogatskaya A, Ström S, Hansson EM, Chien KR, Inzunza J, Hovatta O, Tryggvason K. Long-term self-renewal of human pluripotent stem cells on human recombinant laminin-511. *Nat Biotechnol* 2010; **28**: 611-615 [PMID: 20512123 DOI: 10.1038/nbt.1620]

94 **Mei Y**, Saha K, Bogatyrev SR, Yang J, Hook AL, Kalcioglu ZI, Cho SW, Mitalipova M, Pyzocha N, Rojas F, Van Vliet KJ, Davies MC, Alexander MR, Langer R, Jaenisch R, Anderson DG. Combinatorial development of biomaterials for clonal growth of human pluripotent stem cells. *Nat Mater* 2010; **9**: 768-778 [PMID: 20729850 DOI: 10.1038/nmat2812]

95 **Lu HF**, Narayanan K, Lim SX, Gao S, Leong MF, Wan AC. A 3D microfibrous scaffold for long-term human pluripotent stem cell self-renewal under chemically defined conditions. *Biomaterials* 2012; **33**: 2419-2430 [PMID: 22196900 DOI: 10.1016/j.biomaterials.2011.11.077]

96 **Draper JS**, Moore HD, Ruban LN, Gokhale PJ, Andrews PW. Culture and characterization of human embryonic stem cells. *Stem Cells Dev* 2004; **13**: 325-336 [PMID: 15345125 DOI: 10.1089/scd.2004.13.325]

97 **Ludwig TE**, Levenstein ME, Jones JM, Berggren WT, Mitchen ER, Frane JL, Crandall LJ, Daigh CA, Conard KR, Piekarczyk MS, Llanas RA, Thomson JA. Derivation of human embryonic stem cells in defined conditions. *Nat Biotechnol* 2006; **24**: 185-187 [PMID: 16388305 DOI: 10.1038/nbt1177]

98 **Meng G**, Liu S, Rancourt DE. Synergistic effect of medium, matrix, and exogenous factors on the adhesion and growth of human pluripotent stem cells under defined, xeno-free conditions. *Stem Cells Dev* 2012; **21**: 2036-2048 [PMID: 22149941 DOI: 10.1089/scd.2011.0489]

99 **Sugii S**, Kida Y, Kawamura T, Suzuki J, Vassena R, Yin YQ, Lutz MK, Berggren WT, Izpisúa Belmonte JC, Evans RM. Human and mouse adipose-derived cells support feeder-independent induction of pluripotent stem cells. *Proc Natl Acad Sci U S A* 2010; **107**: 3558-3563 [PMID: 20133714 DOI: 10.1073/pnas.0910172106]

100 **Nakagawa M**, Taniguchi Y, Senda S, Takizawa N, Ichisaka T, Asano K, Morizane A, Doi D, Takahashi J, Nishizawa M, Yoshida Y, Toyoda T, Osafune K, Sekiguchi K, Yamanaka S. A novel efficient feeder-free culture system for the derivation of human induced pluripotent stem cells. *Sci Rep* 2014; **4**: 3594 [PMID: 24399248 DOI: 10.1038/srep03594]

101 **Newman AM**, Cooper JB. Lab-specific gene expression signatures in pluripotent stem cells. *Cell Stem Cell* 2010; **7**: 258-262 [PMID: 20682451 DOI: 10.1016/j.stem.2010.06.016]

102 **Miura K**, Okada Y, Aoi T, Okada A, Takahashi K, Okita K, Nakagawa M, Koyanagi M, Tanabe K, Ohnuki M, Ogawa D, Ikeda E, Okano H, Yamanaka S. Variation in the safety of induced pluripotent stem cell lines. *Nat Biotechnol* 2009; **27**: 743-745 [PMID: 19590502 DOI: 10.1038/nbt.1554]

103 **Kim K**, Doi A, Wen B, Ng K, Zhao R, Cahan P, Kim J, Aryee MJ, Ji H, Ehrlich LI, Yabuuchi A, Takeuchi A, Cunniff KC, Hongguang H, McKinney-Freeman S, Naveiras O, Yoon TJ, Irizarry RA, Jung N, Seita J, Hanna J, Murakami P, Jaenisch R, Weissleder R, Orkin SH, Weissman IL, Feinberg AP, Daley GQ. Epigenetic memory in induced pluripotent stem cells. *Nature* 2010; **467**: 285-290 [PMID: 20644535 DOI: 10.1038/nature09342]

104 **Polo JM**, Liu S, Figueroa ME, Kulalert W, Eminli S, Tan KY, Apostolou E, Stadtfeld M, Li Y, Shioda T, Natesan S, Wagers AJ, Melnick A, Evans T, Hochedlinger K. Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells. *Nat Biotechnol* 2010; **28**: 848-855 [PMID: 20644536 DOI: 10.1038/nbt.1667]

105 **Ma H**, Morey R, O'Neil RC, He Y, Daughtry B, Schultz MD, Hariharan M, Nery JR, Castanon R, Sabatini K, Thiagarajan RD, Tachibana M, Kang E, Tippner-Hedges R, Ahmed R, Gutierrez NM, Van Dyken C, Polat A, Sugawara A, Sparman M, Gokhale S, Amato P, Wolf DP, Ecker JR, Laurent LC, Mitalipov S. Abnormalities in human pluripotent cells due to reprogramming mechanisms. *Nature* 2014; **511**: 177-183 [PMID: 25008523 DOI: 10.1038/nature13551]

106 **Bar-Nur O**, Russ HA, Efrat S, Benvenisty N. Epigenetic memory and preferential lineage-specific differentiation in induced pluripotent stem cells derived from human pancreatic islet beta cells. *Cell Stem Cell* 2011; **9**: 17-23 [PMID: 21726830 DOI: 10.1016/j.stem.2011.06.007]

107 **Kajiwara M**, Aoi T, Okita K, Takahashi R, Inoue H, Takayama N, Endo H, Eto K, Toguchida J, Uemoto S, Yamanaka S. Donor-dependent variations in hepatic differentiation from human-induced pluripotent stem cells. *Proc Natl Acad Sci U S A* 2012; **109**: 12538-12543 [PMID: 22802639 DOI: 10.1073/pnas.1209979109]

108 **Koyanagi-Aoi M**, Ohnuki M, Takahashi K, Okita K, Noma H, Sawamura Y, Teramoto I, Narita M, Sato Y, Ichisaka T, Amano N, Watanabe A, Morizane A, Yamada Y, Sato T, Takahashi J, Yamanaka S. Differentiation-defective phenotypes revealed by large-scale analyses of human pluripotent stem cells. *Proc Natl Acad Sci U S A* 2013; **110**: 20569-20574 [PMID: 24259714 DOI: 10.1073/pnas.1319061110]

109 **Yamashita A**, Liu S, Woltjen K, Thomas B, Meng G, Hotta A, Takahashi K, Ellis J, Yamanaka S, Rancourt DE. Cartilage tissue engineering identifies abnormal human induced pluripotent stem cells. *Sci Rep* 2013; **3**: 1978 [PMID: 23760219 DOI: 10.1038/srep01978]

110 **Zhao T**, Zhang ZN, Rong Z, Xu Y. Immunogenicity of induced pluripotent stem cells. *Nature* 2011; **474**: 212-215 [PMID: 21572395 DOI: 10.1038/nature10135]

111 **Okita K**, Nagata N, Yamanaka S. Immunogenicity of induced pluripotent stem cells. *Circ Res* 2011; **109**: 720-721 [PMID: 21921270 DOI: 10.1161/RES.0b013e318232e187]

112 **Araki R**, Uda M, Hoki Y, Sunayama M, Nakamura M, Ando S, Sugiura M, Ideno H, Shimada A, Nifuji A, Abe M. Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells. *Nature* 2013; **494**: 100-104 [PMID: 23302801 DOI: 10.1038/nature11807]

113 **Guha P**, Morgan JW, Mostoslavsky G, Rodrigues NP, Boyd AS. Lack of immune response to differentiated cells derived from syngeneic induced pluripotent stem cells. *Cell Stem Cell* 2013; **12**: 407-412 [PMID: 23352605 DOI: 10.1016/j.stem.2013.01.006]

114 **de Almeida PE**, Meyer EH, Kooreman NG, Diecke S, Dey D, Sanchez-Freire V, Hu S, Ebert A, Odegaard J, Mordwinkin NM, Brouwer TP, Lo D, Montoro DT, Longaker MT, Negrin RS, Wu JC. Transplanted terminally differentiated induced pluripotent stem cells are accepted by immune mechanisms similar to self-tolerance. *Nat Commun* 2014; **5**: 3903 [PMID: 24875164 DOI: 10.1038/ncomms4903]

115 **Tang C**, Lee AS, Volkmer JP, Sahoo D, Nag D, Mosley AR, Inlay MA, Ardehali R, Chavez SL, Pera RR, Behr B, Wu JC, Weissman IL, Drukker M. An antibody against SSEA-5 glycan on human pluripotent stem cells enables removal of teratoma-forming cells. *Nat Biotechnol* 2011; **29**: 829-834 [PMID: 21841799 DOI: 10.1038/nbt.1947]

116 **Ben-David U**, Nudel N, Benvenisty N. Immunologic and chemical targeting of the tight-junction protein Claudin-6 eliminates tumorigenic human pluripotent stem cells. *Nat Commun* 2013; **4**: 1992 [PMID: 23778593 DOI: 10.1038/ncomms2992]

117 **Tohyama S**, Hattori F, Sano M, Hishiki T, Nagahata Y, Matsuura T, Hashimoto H, Suzuki T, Yamashita H, Satoh Y, Egashira T, Seki T, Muraoka N, Yamakawa H, Ohgino Y, Tanaka T, Yoichi M, Yuasa S, Murata M, Suematsu M, Fukuda K. Distinct metabolic flow enables large-scale purification of mouse and human pluripotent stem cell-derived cardiomyocytes. *Cell Stem Cell* 2013; **12**: 127-137 [PMID: 23168164 DOI: 10.1016/j.stem.2012.09.013]

118 **Taylor CJ**, Peacock S, Chaudhry AN, Bradley JA, Bolton EM. Generating an iPSC bank for HLA-matched tissue transplantation based on known donor and recipient HLA types. *Cell Stem Cell* 2012; **11**: 147-152 [PMID: 22862941 DOI: 10.1016/j.stem.2012.07.014]

119 **Nakatsuji N**, Nakajima F, Tokunaga K. HLA-haplotype banking and iPS cells. *Nat Biotechnol* 2008; **26**: 739-740 [PMID: 18612291 DOI: 10.1038/nbt0708-739]

120 **Cyranoski D**. Stem-cell pioneer banks on future therapies. *Nature* 2012; **488**: 139 [PMID: 22874941 DOI: 10.1038/488139a]

**P-Reviewer:** Chen F, Chhabra A, Patanè S **S-Editor:** Tian YL

**L-Editor: E-Editor:**